Download PDF
Semin Respir Crit Care Med 2019; 40(06): 825-841
DOI: 10.1055/s-0039-1697591
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Gastrointestinal and Hepatobiliary Disease in Cystic Fibrosis

Megan E. Gabel‡   *
1   Division of Pediatric Gastroenterology, Golisano Children's Hospital at Strong, University of Rochester, Rochester, New York
,
Gary J. Galante‡   *
2   Section of Pediatric Gastroenterology, Hepatology and Nutrition, Alberta Children's Hospital, University of Calgary, Calgary, Alberta
,
Steven D. Freedman
3   Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
28 October 2019 (online)

    Permissions and Reprints

Abstract

Cystic fibrosis (CF) is a multiorgan disease, and gastrointestinal (GI) manifestations can contribute to significant morbidity and mortality for individuals with CF. Up to 85% of patients with CF experience GI symptoms, thus addressing the GI aspects of this disease is paramount. With the advent of highly effective CF transmembrane conductance regulator modulators that are increasingly available, many individuals with CF now have significantly improved life expectancy. With these advances, GI manifestations that can be a detriment to quality of life such as gastroesophageal reflux disease, dysbiosis, and chronic abdominal pain have become a priority for patients and caregivers. In addition, as individuals have increased longevity, it has become essential for care providers to be aware of topics such as hepatobiliary disease and colorectal cancer screening. An understanding of the wide scope of GI manifestations in CF can enable providers to optimize the overall health and well-being of their patients. In this review, we aim to provide an up-to-date overview of key aspects of GI and hepatic disease in CF.

Keywords

meconium ileus - gastroesophageal reflux disease - distal intestinal obstruction syndrome - dysbiosis - hepatobiliary - pancreatic function

* Both the author contributed equally to the article.


 

  • References

  • 1 Brodzicki J, Trawińska-Bartnicka M, Korzon M. Frequency, consequences and pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis. Med Sci Monit 2002; 8 (07) CR529-CR537
    PubMedGoogle Scholar
  • 2 Pauwels A, Blondeau K, Mertens V. , et al. Gastric emptying and different types of reflux in adult patients with cystic fibrosis. Aliment Pharmacol Ther 2011; 34 (07) 799-807
    CrossrefPubMedGoogle Scholar
  • 3 Robinson NB, DiMango E. Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease. Ann Am Thorac Soc 2014; 11 (06) 964-968
    CrossrefPubMedGoogle Scholar
  • 4 Cucchiara S, Santamaria F, Andreotti MR. , et al. Mechanisms of gastro-oesophageal reflux in cystic fibrosis. Arch Dis Child 1991; 66 (05) 617-622
    CrossrefPubMedGoogle Scholar
  • 5 Pauwels A, Blondeau K, Dupont LJ, Sifrim D. Mechanisms of increased gastroesophageal reflux in patients with cystic fibrosis. Am J Gastroenterol 2012; 107 (09) 1346-1353
    CrossrefPubMedGoogle Scholar
  • 6 Dimango E, Walker P, Keating C. , et al. Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis. BMC Pulm Med 2014; 14: 21
    CrossrefPubMedGoogle Scholar
  • 7 Pauwels A, Decraene A, Blondeau K. , et al. Bile acids in sputum and increased airway inflammation in patients with cystic fibrosis. Chest 2012; 141 (06) 1568-1574
    CrossrefPubMedGoogle Scholar
  • 8 Corral JE, Dye CW, Mascarenhas MR, Barkin JS, Salathe M, Moshiree B. Is gastroparesis found more frequently in patients with cystic fibrosis? A systematic review. Scientifica (Cairo) 2016; 2016: 2918139
    PubMedGoogle Scholar
  • 9 Hauser B, De Schepper J, Malfroot A. , et al. Gastric emptying and gastro-oesophageal reflux in children with cystic fibrosis. J Cyst Fibros 2016; 15 (04) 540-547
    CrossrefPubMedGoogle Scholar
  • 10 Kuo P, Stevens JE, Russo A. , et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab 2011; 96 (05) E851-E855
    CrossrefPubMedGoogle Scholar
  • 11 Mertens V, Blondeau K, Pauwels A. , et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig Dis Sci 2009; 54 (05) 972-979
    CrossrefPubMedGoogle Scholar
  • 12 Samson C, Tamalet A, Thien HV. , et al. Long-term effects of azithromycin in patients with cystic fibrosis. Respir Med 2016; 117: 1-6
    CrossrefPubMedGoogle Scholar
  • 13 Tonelli AR, Drane WE, Collins DP, Nichols W, Antony VB, Olson EL. Erythromycin improves gastric emptying half-time in adult cystic fibrosis patients with gastroparesis. J Cyst Fibros 2009; 8 (03) 193-197
    CrossrefPubMedGoogle Scholar
  • 14 Sheikh SI, Ryan-Wenger NA, McCoy KS. Outcomes of surgical management of severe GERD in patients with cystic fibrosis. Pediatr Pulmonol 2013; 48 (06) 556-562
    CrossrefPubMedGoogle Scholar
  • 15 Davis Jr RD, Lau CL, Eubanks S. , et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg 2003; 125 (03) 533-542
    CrossrefPubMedGoogle Scholar
  • 16 Cantu III E, Appel III JZ, Hartwig MG. , et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004; 78 (04) 1142-1151 , discussion 1142–1151
    CrossrefPubMedGoogle Scholar
  • 17 Dhaliwal J, Leach S, Katz T. , et al. Intestinal inflammation and impact on growth in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2015; 60 (04) 521-526
    CrossrefPubMedGoogle Scholar
  • 18 Strong TV, Boehm K, Collins FS. Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization. J Clin Invest 1994; 93 (01) 347-354
    CrossrefPubMedGoogle Scholar
  • 19 De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med 2013; 3 (09) a009753
    PubMedGoogle Scholar
  • 20 Lewindon PJ, Robb TA, Moore DJ, Davidson GP, Martin AJ. Bowel dysfunction in cystic fibrosis: importance of breath testing. J Paediatr Child Health 1998; 34 (01) 79-82
    CrossrefPubMedGoogle Scholar
  • 21 Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K. Risk factors for small bowel bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr 2007; 44 (02) 212-218
    CrossrefPubMedGoogle Scholar
  • 22 Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 2013; 38 (07) 674-688
    CrossrefPubMedGoogle Scholar
  • 23 Dorsey J, Gonska T. Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the cystic fibrosis intestine. J Cyst Fibros 2017; 16 (Suppl. 02) S14-S23
    PubMedGoogle Scholar
  • 24 Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun 2004; 72 (10) 6040-6049
    CrossrefPubMedGoogle Scholar
  • 25 Lisowska A, Madry E, Pogorzelski A, Szydłowski J, Radzikowski A, Walkowiak J. Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis. Scand J Clin Lab Invest 2010; 70 (05) 322-326
    CrossrefPubMedGoogle Scholar
  • 26 Barbara G, Stanghellini V, Brandi G. , et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol 2005; 100 (11) 2560-2568
    CrossrefPubMedGoogle Scholar
  • 27 De Lisle RC. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007; 293 (01) G104-G111
    CrossrefPubMedGoogle Scholar
  • 28 De Lisle RC, Roach E, Jansson K. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007; 293 (03) G577-G584
    CrossrefPubMedGoogle Scholar
  • 29 Hedsund C, Gregersen T, Joensson IM, Olesen HV, Krogh K. Gastrointestinal transit times and motility in patients with cystic fibrosis. Scand J Gastroenterol 2012; 47 (8–9): 920-926
    CrossrefPubMedGoogle Scholar
  • 30 Rovner AJ, Schall JI, Mondick JT, Zhuang H, Mascarenhas MR. Delayed small bowel transit in children with cystic fibrosis and pancreatic insufficiency. J Pediatr Gastroenterol Nutr 2013; 57 (01) 81-84
    CrossrefPubMedGoogle Scholar
  • 31 Werlin SL, Benuri-Silbiger I, Kerem E. , et al. Evidence of intestinal inflammation in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2010; 51 (03) 304-308
    CrossrefPubMedGoogle Scholar
  • 32 Lloyd-Still JD. Crohn's disease and cystic fibrosis. Dig Dis Sci 1994; 39 (04) 880-885
    CrossrefPubMedGoogle Scholar
  • 33 Condino AA, Hoffenberg EJ, Accurso F. , et al. Frequency of ASCA seropositivity in children with cystic fibrosis. J Pediatr Gastroenterol Nutr 2005; 41 (01) 23-26
    CrossrefPubMedGoogle Scholar
  • 34 Van Biervliet S, Declercq D, Somerset S. Clinical effects of probiotics in cystic fibrosis patients: a systematic review. Clin Nutr ESPEN 2017; 18: 37-43
    PubMedGoogle Scholar
  • 35 Ananthan A, Balasubramanian H, Rao S, Patole S. Probiotic supplementation in children with cystic fibrosis-a systematic review. Eur J Pediatr 2016; 175 (10) 1255-1266
    CrossrefPubMedGoogle Scholar
  • 36 Gelfond D, Heltshe S, Ma C. , et al. Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol 2017; 8 (03) e81
    CrossrefPubMedGoogle Scholar
  • 37 Ooi CY, Syed SA, Rossi L. , et al. Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation. Sci Rep 2018; 8 (01) 17834
    CrossrefPubMedGoogle Scholar
  • 38 Sermet-Gaudelus I, De Villartay P, de Dreuzy P. , et al. Pain in children and adults with cystic fibrosis: a comparative study. J Pain Symptom Manage 2009; 38 (02) 281-290
    CrossrefPubMedGoogle Scholar
  • 39 Lusman SS, Grand R. Approach to chronic abdominal pain in cystic fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S24-S31
    PubMedGoogle Scholar
  • 40 Fluge G, Olesen HV, Gilljam M. , et al. Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic fibrosis patients. J Cyst Fibros 2009; 8 (03) 198-202
    CrossrefPubMedGoogle Scholar
  • 41 Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2010. Bethesda, MD: Cystic Fibrosis Foundation; 2010
    Google Scholar
  • 42 Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008; 372 (9636): 415-417
    CrossrefPubMedGoogle Scholar
  • 43 Carlyle BE, Borowitz DS, Glick PL. A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. J Pediatr Surg 2012; 47 (04) 772-781
    CrossrefPubMedGoogle Scholar
  • 44 Chen EY, Yang N, Quinton PM, Chin WC. A new role for bicarbonate in mucus formation. Am J Physiol Lung Cell Mol Physiol 2010; 299 (04) L542-L549
    CrossrefPubMedGoogle Scholar
  • 45 Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest 2009; 119 (09) 2613-2622
    CrossrefPubMedGoogle Scholar
  • 46 Olivier AK, Gibson-Corley KN, Meyerholz DK. Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology. Am J Physiol Gastrointest Liver Physiol 2015; 308 (06) G459-G471
    CrossrefPubMedGoogle Scholar
  • 47 Allan JL, Robbie M, Phelan PD, Danks DM. Familial occurrence of meconium ileus. Eur J Pediatr 1981; 135 (03) 291-292
    CrossrefPubMedGoogle Scholar
  • 48 Blackman SM, Deering-Brose R, McWilliams R. , et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology 2006; 131 (04) 1030-1039
    CrossrefPubMedGoogle Scholar
  • 49 Mornet E, Simon-Bouy B, Serre JL. , et al. Genetic differences between cystic fibrosis with and without meconium ileus. Lancet 1988; 1 (8582): 376-378
    PubMedGoogle Scholar
  • 50 Dorfman R, Li W, Sun L. , et al. Modifier gene study of meconium ileus in cystic fibrosis: statistical considerations and gene mapping results. Hum Genet 2009; 126 (06) 763-778
    CrossrefPubMedGoogle Scholar
  • 51 Scotet V, Duguépéroux I, Audrézet MP. , et al. Focus on cystic fibrosis and other disorders evidenced in fetuses with sonographic finding of echogenic bowel: 16-year report from Brittany, France. Am J Obstet Gynecol 2010; 203 (06) 592.e1-592.e6
    CrossrefPubMedGoogle Scholar
  • 52 Ruiz MJ, Thatch KA, Fisher JC, Simpson LL, Cowles RA. Neonatal outcomes associated with intestinal abnormalities diagnosed by fetal ultrasound. J Pediatr Surg 2009; 44 (01) 71-74 , discussion 74–75
    CrossrefPubMedGoogle Scholar
  • 53 Sathe M, Houwen R. Meconium ileus in cystic fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S32-S39
    PubMedGoogle Scholar
  • 54 Bahado-Singh R, Morotti R, Copel JA, Mahoney MJ. Hyperechoic fetal bowel: the perinatal consequences. Prenat Diagn 1994; 14 (10) 981-987
    CrossrefPubMedGoogle Scholar
  • 55 Escobar MA, Grosfeld JL, Burdick JJ. , et al. Surgical considerations in cystic fibrosis: a 32-year evaluation of outcomes. Surgery 2005; 138 (04) 560-571 , discussion 571–572
    CrossrefPubMedGoogle Scholar
  • 56 Rescorla FJ, Grosfeld JL. Contemporary management of meconium ileus. World J Surg 1993; 17 (03) 318-325
    CrossrefPubMedGoogle Scholar
  • 57 Neuhauser EB. Roentgen changes associated with pancreatic insufficiency in early life. Radiology 1946; 46: 319-328
    CrossrefPubMedGoogle Scholar
  • 58 Noblett HR. Treatment of uncomplicated meconium ileus by Gastrografin enema: a preliminary report. J Pediatr Surg 1969; 4 (02) 190-197
    CrossrefPubMedGoogle Scholar
  • 59 Mushtaq I, Wright VM, Drake DP, Mearns MB, Wood CB. Meconium ileus secondary to cystic fibrosis. The East London experience. Pediatr Surg Int 1998; 13 (5–6): 365-369
    CrossrefPubMedGoogle Scholar
  • 60 Karimi A, Gorter RR, Sleeboom C, Kneepkens CM, Heij HA. Issues in the management of simple and complex meconium ileus. Pediatr Surg Int 2011; 27 (09) 963-968
    CrossrefPubMedGoogle Scholar
  • 61 Caniano DA, Beaver BL. Meconium ileus: a fifteen-year experience with forty-two neonates. Surgery 1987; 102 (04) 699-703
    PubMedGoogle Scholar
  • 62 Copeland DR, St Peter SD, Sharp SW. , et al. Diminishing role of contrast enema in simple meconium ileus. J Pediatr Surg 2009; 44 (11) 2130-2132
    CrossrefPubMedGoogle Scholar
  • 63 Ein SH, Shandling B, Reilly BJ, Stephens CA. Bowel perforation with nonoperative treatment of meconium ileus. J Pediatr Surg 1987; 22 (02) 146-147
    CrossrefPubMedGoogle Scholar
  • 64 Fitzgerald R, Conlon K. Use of the appendix stump in the treatment of meconium ileus. J Pediatr Surg 1989; 24 (09) 899-900
    CrossrefPubMedGoogle Scholar
  • 65 Bishop HC, Koop CE. Management of meconium ileus; resection, Roux-en-Y anastomosis and ileostomy irrigation with pancreatic enzymes. Ann Surg 1957; 145 (03) 410-414
    PubMedGoogle Scholar
  • 66 Santulli TV, Blanc WA. Congenital atresia of the intestine: pathogenesis and treatment. Ann Surg 1961; 154: 939-948
    PubMedGoogle Scholar
  • 67 Jawaheer J, Khalil B, Plummer T. , et al. Primary resection and anastomosis for complicated meconium ileus: a safe procedure?. Pediatr Surg Int 2007; 23 (11) 1091-1093
    CrossrefPubMedGoogle Scholar
  • 68 Del Pin CA, Czyrko C, Ziegler MM, Scanlin TF, Bishop HC. Management and survival of meconium ileus. A 30-year review. Ann Surg 1992; 215 (02) 179-185
    CrossrefPubMedGoogle Scholar
  • 69 Leeuwen L, Magoffin AK, Fitzgerald DA, Cipolli M, Gaskin KJ. Cholestasis and meconium ileus in infants with cystic fibrosis and their clinical outcomes. Arch Dis Child 2014; 99 (05) 443-447
    CrossrefPubMedGoogle Scholar
  • 70 Efrati O, Nir J, Fraser D. , et al. Meconium ileus in patients with cystic fibrosis is not a risk factor for clinical deterioration and survival: the Israeli Multicenter Study. J Pediatr Gastroenterol Nutr 2010; 50 (02) 173-178
    CrossrefPubMedGoogle Scholar
  • 71 Munck A, Gérardin M, Alberti C. , et al. Clinical outcome of cystic fibrosis presenting with or without meconium ileus: a matched cohort study. J Pediatr Surg 2006; 41 (09) 1556-1560
    CrossrefPubMedGoogle Scholar
  • 72 Houwen RH, van der Doef HP, Sermet I. , et al; ESPGHAN Cystic Fibrosis Working Group. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr 2010; 50 (01) 38-42
    CrossrefPubMedGoogle Scholar
  • 73 Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M. ; ECFS. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros 2011; 10 (Suppl. 02) S24-S28
    PubMedGoogle Scholar
  • 74 Dray X, Bienvenu T, Desmazes-Dufeu N, Dusser D, Marteau P, Hubert D. Distal intestinal obstruction syndrome in adults with cystic fibrosis. Clin Gastroenterol Hepatol 2004; 2 (06) 498-503
    CrossrefPubMedGoogle Scholar
  • 75 Andersen HO, Hjelt K, Waever E, Overgaard K. The age-related incidence of meconium ileus equivalent in a cystic fibrosis population: the impact of high-energy intake. J Pediatr Gastroenterol Nutr 1990; 11 (03) 356-360
    CrossrefPubMedGoogle Scholar
  • 76 Munck A, Alberti C, Colombo C. , et al; CF/Pancreas ESPGHAN Working Group and DIOS Study Group. International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: associated factors and outcome. J Cyst Fibros 2016; 15 (04) 531-539
    CrossrefPubMedGoogle Scholar
  • 77 Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. Dig Dis Sci 2013; 58 (08) 2275-2281
    CrossrefPubMedGoogle Scholar
  • 78 Risse PA, Kachmar L, Matusovsky OS. , et al. Ileal smooth muscle dysfunction and remodeling in cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2012; 303 (01) G1-G8
    CrossrefPubMedGoogle Scholar
  • 79 Ooi CY, Jeyaruban C, Lau J. , et al. High ambient temperature and risk of intestinal obstruction in cystic fibrosis. J Paediatr Child Health 2016; 52 (04) 430-435
    CrossrefPubMedGoogle Scholar
  • 80 Gilljam M, Chaparro C, Tullis E, Chan C, Keshavjee S, Hutcheon M. GI complications after lung transplantation in patients with cystic fibrosis. Chest 2003; 123 (01) 37-41
    CrossrefPubMedGoogle Scholar
  • 81 Morton JR, Ansari N, Glanville AR, Meagher AP, Lord RV. Distal intestinal obstruction syndrome (DIOS) in patients with cystic fibrosis after lung transplantation. J Gastrointest Surg 2009; 13 (08) 1448-1453
    CrossrefPubMedGoogle Scholar
  • 82 Abraham JM, Taylor CJ. Cystic Fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros 2017; 16 (Suppl. 02) S40-S49
    PubMedGoogle Scholar
  • 83 Pall H, Zacur GM, Kramer RE. , et al. Bowel preparation for pediatric colonoscopy: report of the NASPGHAN endoscopy and procedures committee. J Pediatr Gastroenterol Nutr 2014; 59 (03) 409-416
    CrossrefPubMedGoogle Scholar
  • 84 Zahra M, Frederick C, Thomas R, Iqbal V, Borowitz D. Gastrografin enemas for treatment of distal intestinal obstruction syndrome in children and adults with cystic fibrosis. J Pharm Nutr Sci 2014; 4 (02) 76-80
    CrossrefPubMedGoogle Scholar
  • 85 Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev 2007; 8 (01) 24-29
    CrossrefPubMedGoogle Scholar
  • 86 Williams K, Huntington S, Shaw N, Conway SP, Peckham D. Prucalopride: a review of the first 12 months of use. J Cyst Fibros 2012; 11 (01) S115 . Available at: https://www.cysticfibrosisjournal.com/article/S1569-1993(12)60398-1/pdf . Accessed September 10, 2019
    PubMedGoogle Scholar
  • 87 Lavie M, Manovitz T, Vilozni D. , et al. Long-term follow-up of distal intestinal obstruction syndrome in cystic fibrosis. World J Gastroenterol 2015; 21 (01) 318-325
    CrossrefPubMedGoogle Scholar
  • 88 van der Doef HP, Kokke FT, Beek FJ, Woestenenk JW, Froeling SP, Houwen RH. Constipation in pediatric cystic fibrosis patients: an underestimated medical condition. J Cyst Fibros 2010; 9 (01) 59-63
    CrossrefPubMedGoogle Scholar
  • 89 Gelfond D, Borowitz D. Gastrointestinal complications of cystic fibrosis. Clin Gastroenterol Hepatol 2013; 11 (04) 333-342 , quiz e30–e31
    CrossrefPubMedGoogle Scholar
  • 90 Sinaasappel M, Stern M, Littlewood J. , et al. Nutrition in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2002; 1 (02) 51-75
    CrossrefPubMedGoogle Scholar
  • 91 Assis DN, Freedman SD. Gastrointestinal disorders in cystic fibrosis. Clin Chest Med 2016; 37 (01) 109-118
    PubMedGoogle Scholar
  • 92 Tabbers MM, DiLorenzo C, Berger MY. , et al; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; North American Society for Pediatric Gastroenterology. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. J Pediatr Gastroenterol Nutr 2014; 58 (02) 258-274
    CrossrefPubMedGoogle Scholar
  • 93 Clark JH, Russell GJ, Fitzgerald JF, Nagamori KE. Serum beta-carotene, retinol, and alpha-tocopherol levels during mineral oil therapy for constipation. Am J Dis Child 1987; 141 (11) 1210-1212
    PubMedGoogle Scholar
  • 94 Sharif F, Crushell E, O'Driscoll K, Bourke B. Liquid paraffin: a reappraisal of its role in the treatment of constipation. Arch Dis Child 2001; 85 (02) 121-124
    CrossrefPubMedGoogle Scholar
  • 95 Camilleri M, Piessevaux H, Yiannakou Y. , et al. Efficacy and safety of prucalopride in chronic constipation: an integrated analysis of six randomized, controlled clinical trials. Dig Dis Sci 2016; 61 (08) 2357-2372
    CrossrefPubMedGoogle Scholar
  • 96 O'Brien CE, Anderson PJ, Stowe CD. Lubiprostone for constipation in adults with cystic fibrosis: a pilot study. Ann Pharmacother 2011; 45 (09) 1061-1066
    CrossrefPubMedGoogle Scholar
  • 97 McHugh DR, Cotton CU, Moss FJ. , et al. Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3. Am J Physiol Gastrointest Liver Physiol 2018; 315 (05) G868-G878
    CrossrefPubMedGoogle Scholar
  • 98 Holsclaw DS, Rocmans C, Shwachman H. Intussusception in patients with cystic fibrosis. Pediatrics 1971; 48 (01) 51-58
    PubMedGoogle Scholar
  • 99 Hafen GM, Taylor AC, Oliver MR. , et al. Intussusceptions arising from two different sites in a child with cystic fibrosis. Pediatr Pulmonol 2005; 40 (04) 358-361
    CrossrefPubMedGoogle Scholar
  • 100 Beck AR, Aterman K. Intestinal obstruction and mucoviscidosis. Gastroenterologia 1966; 106 (02) 86-96
    PubMedGoogle Scholar
  • 101 Chaun H. Colonic disorders in adult cystic fibrosis. Can J Gastroenterol 2001; 15 (09) 586-590
    CrossrefPubMedGoogle Scholar
  • 102 Agrons GA, Corse WR, Markowitz RI, Suarez ES, Perry DR. Gastrointestinal manifestations of cystic fibrosis: radiologic-pathologic correlation. Radiographics 1996; 16 (04) 871-893
    CrossrefPubMedGoogle Scholar
  • 103 Lavelle LP, McEvoy SH, Ni Mhurchu E. , et al. Cystic fibrosis below the diaphragm: abdominal findings in adult patients. Radiographics 2015; 35 (03) 680-695
    CrossrefPubMedGoogle Scholar
  • 104 Timothy Adewale A, Rowe SM, Solomon GM. Colocolonic intussusception in an adult cystic fibrosis patient. J Cyst Fibros 2019; 18 (02) e11-e13
    CrossrefPubMedGoogle Scholar
  • 105 Coughlin JP, Gauderer MW, Stern RC, Doershuk CF, Izant Jr RJ, Zollinger Jr RM. The spectrum of appendiceal disease in cystic fibrosis. J Pediatr Surg 1990; 25 (08) 835-839
    CrossrefPubMedGoogle Scholar
  • 106 Lardenoye SW, Puylaert JB, Smit MJ, Holscher HC. Appendix in children with cystic fibrosis: US features. Radiology 2004; 232 (01) 187-189
    CrossrefPubMedGoogle Scholar
  • 107 Keyzer C, Knoop C, Van Wettere M. , et al. Cystic fibrosis: unenhanced CT description of the appendix in asymptomatic adults. AJR Am J Roentgenol 2014; 202 (04) 759-764
    CrossrefPubMedGoogle Scholar
  • 108 McCarthy VP, Mischler EH, Hubbard VS, Chernick MS, di Sant'Agnese PA. Appendiceal abscess in cystic fibrosis. A diagnostic challenge. Gastroenterology 1984; 86 (03) 564-568
    CrossrefPubMedGoogle Scholar
  • 109 Shields MD, Levison H, Reisman JJ, Durie PR, Canny GJ. Appendicitis in cystic fibrosis. Arch Dis Child 1991; 66 (03) 307-310
    CrossrefPubMedGoogle Scholar
  • 110 Bauer MP, Farid A, Bakker M, Hoek RA, Kuijper EJ, van Dissel JT. Patients with cystic fibrosis have a high carriage rate of non-toxigenic Clostridium difficile. Clin Microbiol Infect 2014; 20 (07) O446-O449
    CrossrefPubMedGoogle Scholar
  • 111 Freedman SD, Uppot RN, Mino-Kenudson M. Case records of the Massachusetts General Hospital. Case 26-2009. A 34-year-old man with cystic fibrosis with abdominal pain and distention. N Engl J Med 2009; 361 (08) 807-816
    CrossrefPubMedGoogle Scholar
  • 112 Piccolo F, Tai AS, Ee H, Mulrennan S, Bell S, Ryan G. Clostridium difficile infection in cystic fibrosis: an uncommon but life-threatening complication. Respirol Case Rep 2016; 5 (01) e00204
    PubMedGoogle Scholar
  • 113 McDonald LC, Gerding DN, Johnson S. , et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society Of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66 (07) 987-994
    CrossrefPubMedGoogle Scholar
  • 114 Smyth RL, van Velzen D, Smyth AR, Lloyd DA, Heaf DP. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 343 (8889): 85-86
    CrossrefPubMedGoogle Scholar
  • 115 FitzSimmons SC, Burkhart GA, Borowitz D. , et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336 (18) 1283-1289
    CrossrefPubMedGoogle Scholar
  • 116 Freiman JP, FitzSimmons SC. Colonic strictures in patients with cystic fibrosis: results of a survey of 114 cystic fibrosis care centers in the United States. J Pediatr Gastroenterol Nutr 1996; 22 (02) 153-156
    CrossrefPubMedGoogle Scholar
  • 117 Schwarzenberg SJ, Wielinski CL, Shamieh I. , et al. Cystic fibrosis-associated colitis and fibrosing colonopathy. J Pediatr 1995; 127 (04) 565-570
    CrossrefPubMedGoogle Scholar
  • 118 Lloyd-Still JD. Cystic fibrosis and colonic strictures. A new “iatrogenic” disease. J Clin Gastroenterol 1995; 21 (01) 2-5
    CrossrefPubMedGoogle Scholar
  • 119 Serban DE, Florescu P, Miu N. Fibrosing colonopathy revealing cystic fibrosis in a neonate before any pancreatic enzyme supplementation. J Pediatr Gastroenterol Nutr 2002; 35 (03) 356-359
    CrossrefPubMedGoogle Scholar
  • 120 Demeyer S, De Boeck K, Witters P, Cosaert K. Beyond pancreatic insufficiency and liver disease in cystic fibrosis. Eur J Pediatr 2016; 175 (07) 881-894
    CrossrefPubMedGoogle Scholar
  • 121 Almberger M, Iannicelli E, Antonelli M, Matrunola M, Cimino G, Passariello R. The role of MRI in the intestinal complications in cystic fibrosis. Clin Imaging 2001; 25 (05) 344-348
    CrossrefPubMedGoogle Scholar
  • 122 Terheggen G, Dieninghoff D, Rietschel E, Drebber U, Kruis W, Leifeld L. Successful non-invasive treatment of stricturing fibrosing colonopathy in an adult patient. Eur J Med Res 2011; 16 (09) 411-414
    CrossrefPubMedGoogle Scholar
  • 123 Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J Natl Cancer Inst 2013; 105 (02) 122-129
    CrossrefPubMedGoogle Scholar
  • 124 Neglia JP, FitzSimmons SC, Maisonneuve P. , et al; Cystic Fibrosis and Cancer Study Group. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study group. N Engl J Med 1995; 332 (08) 494-499
    CrossrefPubMedGoogle Scholar
  • 125 Corriveau S, Sykes J, Stephenson AL. Cystic fibrosis survival: the changing epidemiology. Curr Opin Pulm Med 2018; 24 (06) 574-578
    PubMedGoogle Scholar
  • 126 Kushi LH, Doyle C, McCullough M. , et al; American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012; 62 (01) 30-67
    CrossrefPubMedGoogle Scholar
  • 127 Ren X, Zhang X, Zhang X. , et al. Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health 2009; 123 (08) 540-544
    CrossrefPubMedGoogle Scholar
  • 128 Fink AK, Yanik EL, Marshall BC. , et al. Cancer risk among lung transplant recipients with cystic fibrosis. J Cyst Fibros 2017; 16 (01) 91-97
    CrossrefPubMedGoogle Scholar
  • 129 Mima K, Ogino S, Nakagawa S. , et al. The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surg Oncol 2017; 26 (04) 368-376
    CrossrefPubMedGoogle Scholar
  • 130 Arthur JC, Perez-Chanona E, Mühlbauer M. , et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012; 338 (6103): 120-123
    CrossrefPubMedGoogle Scholar
  • 131 Than BL, Linnekamp JF, Starr TK. , et al. CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 2016; 35 (32) 4179-4187
    CrossrefPubMedGoogle Scholar
  • 132 Niccum DE, Billings JL, Dunitz JM, Khoruts A. Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis. J Cyst Fibros 2016; 15 (04) 548-553
    CrossrefPubMedGoogle Scholar
  • 133 Hadjiliadis D, Khoruts A, Zauber AG, Hempstead SE, Maisonneuve P, Lowenfels AB. ; Cystic Fibrosis Colorectal Cancer Screening Task Force. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology 2018; 154 (03) 736-745.e14
    CrossrefPubMedGoogle Scholar
  • 134 Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993; 105 (06) 1857-1864
    CrossrefPubMedGoogle Scholar
  • 135 Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 2004; 6 (03) 231-239
    CrossrefPubMedGoogle Scholar
  • 136 Leung DH, Narkewicz MR. Cystic Fibrosis-related cirrhosis. J Cyst Fibros 2017; 16 (Suppl. 02) S50-S61
    PubMedGoogle Scholar
  • 137 Hillaire S, Cazals-Hatem D, Bruno O. , et al. Liver transplantation in adult cystic fibrosis: clinical, imaging, and pathological evidence of obliterative portal venopathy. Liver Transpl 2017; 23 (10) 1342-1347
    CrossrefPubMedGoogle Scholar
  • 138 Witters P, Libbrecht L, Roskams T. , et al. Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension. J Cyst Fibros 2017; 16 (05) e11-e13
    CrossrefPubMedGoogle Scholar
  • 139 Wu H, Vu M, Dhingra S. , et al. Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension. Clin Gastroenterol Hepatol 2018; 17 (10) 2134-2136
    PubMedGoogle Scholar
  • 140 Debray D, Narkewicz MR, Bodewes FAJA. , et al. Cystic fibrosis-related liver disease: research challenges and future perspectives. J Pediatr Gastroenterol Nutr 2017; 65 (04) 443-448
    CrossrefPubMedGoogle Scholar
  • 141 Stonebraker JR, Ooi CY, Pace RG. , et al. Features of severe liver disease with portal hypertension in patients with cystic fibrosis. Clin Gastroenterol Hepatol 2016; 14 (08) 1207.e3-1215.e3
    PubMedGoogle Scholar
  • 142 Colombo C, Battezzati PM, Crosignani A. , et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002; 36 (06) 1374-1382
    CrossrefPubMedGoogle Scholar
  • 143 Koh C, Sakiani S, Surana P. , et al. Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity. Hepatology 2017; 66 (02) 591-601
    CrossrefPubMedGoogle Scholar
  • 144 Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros 2011; 10 (Suppl. 02) S29-S36
    PubMedGoogle Scholar
  • 145 Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30 (05) 1151-1158
    CrossrefPubMedGoogle Scholar
  • 146 Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 2004; 41 (06) 920-925
    CrossrefPubMedGoogle Scholar
  • 147 Efrati O, Barak A, Modan-Moses D. , et al. Liver cirrhosis and portal hypertension in cystic fibrosis. Eur J Gastroenterol Hepatol 2003; 15 (10) 1073-1078
    CrossrefPubMedGoogle Scholar
  • 148 Bartlett JR, Friedman KJ, Ling SC. , et al; Gene Modifier Study Group. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302 (10) 1076-1083
    CrossrefPubMedGoogle Scholar
  • 149 Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007; 13 (06) 529-536
    CrossrefPubMedGoogle Scholar
  • 150 Lewindon PJ, Puertolas-Lopez MV, Ramm LE. , et al. Accuracy of transient elastography data combined with APRI in detection and staging of liver disease in pediatric patients with cystic fibrosis. Clin Gastroenterol Hepatol 2019 ;(e-pub ahead of print). Doi: 10.1016/j.cgh.2019.03.015
    PubMedGoogle Scholar
  • 151 Boëlle PY, Debray D, Guillot L, Clement A, Corvol H, French CF. ; French CF Modifier Gene Study Investigators. Cystic fibrosis liver disease: outcomes and risk factors in a large cohort of French patients. Hepatology 2019; 69 (04) 1648-1656
    CrossrefPubMedGoogle Scholar
  • 152 Borowitz D, Gelfond D. Intestinal complications of cystic fibrosis. Curr Opin Pulm Med 2013; 19 (06) 676-680
    CrossrefPubMedGoogle Scholar
  • 153 Fawaz R, Baumann U, Ekong U. , et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017; 64 (01) 154-168
    CrossrefPubMedGoogle Scholar
  • 154 Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child 1996; 75 (01) 67-70
    CrossrefPubMedGoogle Scholar
  • 155 Shapira R, Hadzic N, Francavilla R, Koukulis G, Price JF, Mieli-Vergani G. Retrospective review of cystic fibrosis presenting as infantile liver disease. Arch Dis Child 1999; 81 (02) 125-128
    CrossrefPubMedGoogle Scholar
  • 156 Oppenheimer EH, Esterly JR. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr 1975; 86 (05) 683-689
    CrossrefPubMedGoogle Scholar
  • 157 Perkins WG, Klein GL, Beckerman RC. Cystic fibrosis mistaken for idiopathic biliary atresia. Clin Pediatr (Phila) 1985; 24 (02) 107-109
    CrossrefPubMedGoogle Scholar
  • 158 Greenholz SK, Krishnadasan B, Marr C, Cannon R. Biliary obstruction in infants with cystic fibrosis requiring Kasai portoenterostomy. J Pediatr Surg 1997; 32 (02) 175-179 , discussion 179–180
    CrossrefPubMedGoogle Scholar
  • 159 Lewindon PJ, Shepherd RW, Walsh MJ. , et al. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53 (01) 193-201
    CrossrefPubMedGoogle Scholar
  • 160 Treem WR, Stanley CA. Massive hepatomegaly, steatosis, and secondary plasma carnitine deficiency in an infant with cystic fibrosis. Pediatrics 1989; 83 (06) 993-997
    PubMedGoogle Scholar
  • 161 Chen AH, Innis SM, Davidson AG, James SJ. Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine. Am J Clin Nutr 2005; 81 (03) 686-691
    CrossrefPubMedGoogle Scholar
  • 162 Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros 2013; 12 (02) 116-124
    CrossrefPubMedGoogle Scholar
  • 163 Patriquin H, Lenaerts C, Smith L. , et al. Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients. Radiology 1999; 211 (01) 229-232
    CrossrefPubMedGoogle Scholar
  • 164 Angelico M, Gandin C, Canuzzi P. , et al. Gallstones in cystic fibrosis: a critical reappraisal. Hepatology 1991; 14 (05) 768-775
    CrossrefPubMedGoogle Scholar
  • 165 Colombo C, Bertolini E, Assaisso ML, Bettinardi N, Giunta A, Podda M. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 1993; 82 (6–7): 562-565
    CrossrefPubMedGoogle Scholar
  • 166 Vítek L, Carey MC. New pathophysiological concepts underlying pathogenesis of pigment gallstones. Clin Res Hepatol Gastroenterol 2012; 36 (02) 122-129
    CrossrefPubMedGoogle Scholar
  • 167 Kuver R, Lee SP. Calcium binding to biliary mucins is dependent on sodium ion concentration: relevance to cystic fibrosis. Biochem Biophys Res Commun 2004; 314 (02) 330-334
    CrossrefPubMedGoogle Scholar
  • 168 Akata D, Akhan O. Liver manifestations of cystic fibrosis. Eur J Radiol 2007; 61 (01) 11-17
    CrossrefPubMedGoogle Scholar
  • 169 Assis DN, Debray D. Gallbladder and bile duct disease in cystic fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S62-S69
    PubMedGoogle Scholar
  • 170 Beuers U, Maroni L, Elferink RO. The biliary HCO(3)(-) umbrella: experimental evidence revisited. Curr Opin Gastroenterol 2012; 28 (03) 253-257
    CrossrefPubMedGoogle Scholar
  • 171 Fiorotto R, Scirpo R, Trauner M. , et al. Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice. Gastroenterology 2011; 141 (04) 1498-1508 , 1508.e1–1508.e5
    CrossrefPubMedGoogle Scholar
  • 172 Durieu I, Pellet O, Simonot L. , et al. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J Hepatol 1999; 30 (06) 1052-1056
    CrossrefPubMedGoogle Scholar
  • 173 Buxbaum J, Nguyen N, Kulkarni S, Palmer S, Rao A, Selby R. Multidisciplinary treatment of cystic fibrosis-related recurrent pyogenic cholangitis (CF-RPC). Dig Dis Sci 2015; 60 (06) 1801-1804
    CrossrefPubMedGoogle Scholar
  • 174 Perdue DG, Cass OW, Milla C. , et al. Hepatolithiasis and cholangiocarcinoma in cystic fibrosis: a case series and review of the literature. Dig Dis Sci 2007; 52 (10) 2638-2642
    CrossrefPubMedGoogle Scholar
  • 175 Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2017; 9: CD000222
    PubMedGoogle Scholar
  • 176 Mon Martín F, Martín Malagón AI, Arteaga González IJ, Díaz Luís H, Carrillo Pallares AL. Hepatolithiasis in cystic fibrosis: a special condition for surgical treatment. Cir Esp 2014; 92 (09) 634-635
    CrossrefPubMedGoogle Scholar
  • 177 Wilschanski M, Durie PR. Pathology of pancreatic and intestinal disorders in cystic fibrosis. J R Soc Med 1998; 91 (Suppl. 34) 40-49
    PubMedGoogle Scholar
  • 178 Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros 2017; 16 (Suppl. 02) S70-S78
    PubMedGoogle Scholar
  • 179 Borowitz D, Robinson KA, Rosenfeld M. , et al; Cystic Fibrosis Foundation. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155 (6, Suppl): S73-S93
    CrossrefPubMedGoogle Scholar
  • 180 Borowitz D, Baker SS, Duffy L. , et al. Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004; 145 (03) 322-326
    CrossrefPubMedGoogle Scholar
  • 181 Ferrone M, Raimondo M, Scolapio JS. Pancreatic enzyme pharmacotherapy. Pharmacotherapy 2007; 27 (06) 910-920
    CrossrefPubMedGoogle Scholar
  • 182 Proesmans M, De Boeck K. Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr 2003; 162 (11) 760-763
    CrossrefPubMedGoogle Scholar
  • 183 Turck D, Braegger CP, Colombo C. , et al. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016; 35 (03) 557-577
    CrossrefPubMedGoogle Scholar
  • 184 Rosenfeld M, Wainwright CE, Higgins M. , et al; ARRIVAL study group. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med 2018; 6 (07) 545-553
    CrossrefPubMedGoogle Scholar
  • 185 Maqbool A, Pauwels A. Cystic Fibrosis and gastroesophageal reflux disease. J Cyst Fibros 2017; 16 (Suppl. 02) S2-S13
    PubMedGoogle Scholar